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Background: Substantial falls in the mortality of people living with HIV (PLWH) have been observed since the
introduction of antiretroviral therapy (ART) in sub-Saharan Africa. However, access and uptake of ART have
been variable in many countries. We report the excess deaths observed in PLWH before and after the introduc-
tion of ART. We use data from five longitudinal studies in Malawi, South Africa, Tanzania, and Uganda,
members of the network for Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA).
Methods: Individual data from five demographic surveillance sites that conduct HIV testing were used to
estimate mortality attributable to HIV, calculated as the difference between the mortality rates in PLWH and
HIV-negative people. Excess deaths in PLWH were standardized for age and sex differences and summarized
over periods before and after ART became generally available. An exponential regression model was used to
explore differences in the impact of ART over the different sites.
Results: 127,585 adults across the five sites contributed a total of 487,242 person years. Before the
introduction of ART, HIV-attributable mortality ranged from 45 to 88 deaths per 1,000 person years.
Following ART availability, this reduced to 1446 deaths per 1,000 person years. Exponential regression
modeling showed a reduction of more than 50% (HR 0.43, 95% CI: 0.320.58), compared to the period
before ART was available, in mortality at ages 1554 across all five sites.
Discussion: Excess mortality in adults living with HIV has reduced by over 50% in five communities in sub-
Saharan Africa since the advent of ART. However, mortality rates in adults living with HIV are still 10 times
higher than in HIV-negative people, indicating that substantial improvements can be made to reduce mortality
further. This analysis shows differences in the impact across the sites, and contrasts with developed countries
where mortality among PLWH on ART can be similar to that of the general population. Further research is
urgently needed to establish why the different impacts on mortality were observed and how the care and
treatment programmes in these countries can be more effective in reducing mortality further.
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P
rior to the advent of antiretroviral therapy (ART),
observed mortality rates among adults living with
HIV from population-based studies were 1015
times higher than in HIV-negative adults (14). This
indicates that 9095% of deaths in people living with HIV
(PLWH) were excess deaths due to HIV infection and
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(page number not for citation purpose)were therefore attributable to HIV. The proportion of
deaths in PLWH that are due to HIV depends on the
background mortality in the population (5).
Clinic-based data have shown substantial falls in
mortality since the introduction of ART, but mortality
among PLWH is still considerably higher than among
individuals who are HIV-negative. ART programmes
have been shown to have substantial impacts on all-cause
and AIDS mortality in sub-Saharan African countries
(610) despite the poorer survival documented among
people receiving treatment in low-income countries
compared to those in high-income countries (11).
In developing countries, there are many barriers to
effective ART provision. On an individual level, PLWH
who have not received HIV testing and counselling
(HTC), or have not accessed ART clinics, do not receive
treatment (12). Within ART treatment programmes, there
may be inadequate treatment of other infections and
limited social support. Monitoring of immunological
recovery, adherence, and drug resistance is difficult in
many settings, resulting in suboptimal delivery of ART.
Factors that influence wider health, such as food security
and access to health services, also influence the uptake
and effectiveness of ART. All these factors can limit the
impact of ART on mortality (13).
Therefore, in sub-Saharan African countries, where the
relatively recent ARTrollout has been shown to havesome
impact on mortality, further reductions in HIV-positive
mortality may be possible, and this raises the question
of the number of excess deaths in PLWH, even when
treatment programmes are in place. In order to estimate
the extent of the mortality decline among PLWH since the
introduction of ART, and to estimate what further reduc-
tions may be possible, we need data on the HIV serostatus
of the general population, which is not widely available.
This article reports results from studies in Malawi (the
Karonga Prevention Study, London School of Hygiene
andTropicalMedicine),SouthAfrica(theuMkhanyakude
cohort, Africa Centre for Health and Population Studies),
Tanzania (the Kisesa cohort, National Institute for Me-
dical Research), and Uganda (the Masaka-Kyamulibwa
general population cohort, Medical Research Council/
Uganda Virus Research Institute; and the Rakai Health
Sciences Program), which form part of the network for
Analysing Longitudinal Population-based HIV/AIDS
data on Africa (ALPHA), which brings together the sites in
sub-Saharan Africa that collect longitudinal, population-
based demographic data alongside HIV serostatus. These
sites provide unique data on mortality pre- and post-
ART. Demographic data are available for a long period
(starting from 1989), and from five communities in four
countries with different HIV epidemic settings. Data on
HIV serostatus are available from different time points in
some sites; these dates are given in Table 1. These data
permit estimation of mortality rates in PLWH and HIV-
negative people and the extent of excess deaths in PLWH.
Detailed analyses of mortality in each site have been
conducted (1416).
The study sites are in predominantly rural areas. HIV
prevalence is highest in uMkhanyakude [29% among
1549 year olds in 2011 (17)], where the epidemic started
later and reached a higher level than in the other sites
and where ART is helping maintain high prevalence by
avertingdeaths among PLWH. Prevalence in the countries
with more established epidemics is stable; it is substan-
tially lower in Karonga, Kisesa, and Masaka ( 6%) and
intermediate in Rakai. ART is provided through national
treatment programmes, although Masaka delivers ART
through a study clinic rather than a government health
facility.
In this article, we compare the number of excess deaths
in PLWH in three different periods: during the 5 years
before the introduction of ART, at the time during which
eachcountry’sARTprogrammewasestablished,andthe5
years after ART became widely available in each country.
We use an exponential regression model to assess how the
death rate among PLWH has changed relative to that
among HIV-negative people during these same time
periods.
Methods
Data collection methods
This article uses data from 5 of the 10 sites that make up
the ALPHA network. The sites which contributed data
Table 1. Dates for the introduction of ART, the full rollout of ART, and the start of demographic surveillance and HIV serosurveys
Start dates for ART phases
Site
Start of demographic
data collection
Start of HIV
serosurveys
Pre-ART
phase
ART introductory
phase
Post-ART
phase
Karonga August 2002 October 2005 July 2000 July 2005 October 2006
Kisesa May 1994 August 1994 January 2000 March 2005 October 2008
Masaka November 1989 November 1989 January 1999 January 2004 January 2005
Rakai April 1999 April 1999 June 1999 June 2004 June 2006
uMkhanyakude January 2000 October 2002 January 1999 January 2005 January 2007
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(Uganda), Rakai Health Sciences Program (Uganda),
and the Africa Centre (uMkhanyakude, South Africa),
and their fieldwork methods have been described else-
where (1824). Each site runs a demographic surveillance
system (DSS) with linked HIV serostatus information
on adult residents. Four sites have demographic and
HIV status data spanning the three periods of inter-
est surrounding the introduction of ART. The fifth
(Karonga) is included for the purposes of cross-site
comparisons.
Each study site extracted, from their study databases,
information describing time spent resident in the study
area and including dates of exit from the study, due to
death or out-migration. They also extracted all informa-
tion on the HIV status of each study participant. Data
were prepared in a standard format, and data from all
sites were pooled in February 2013.
Data definitions
HIV test information was merged with the residency
episodes. The HIV status during each part of a residency
episode was derived from the test results at specific time
points. To ensure consistency between the classification
of deaths and of exposure time, person years were
classified by HIV status as shown in Table 2. All deaths
occurring in persons with a documented positive HIV test
result arising from an ante-mortem study test were
classified as HIV-related, and these composed the nu-
merator for the HIV-positive mortality rate. Deaths
amongst persons who had recently been tested in the
study and were found to be HIV-negative formed the
numerator for the negative mortality rate.
Data on the introduction of ART in each country were
used to identify three periods: before the introduction of
ART (i.e. no treatment available); a rollout phase
immediately following the introduction of ART, when
ART was assumed to be only partially available; and,
subsequently, a phase when ART was widely available
(Table 1). In these observational study sites, ART was
introduced when national treatment programmes started
to provide services. These periods therefore do not
precisely align with the demographic and serosurvey
activities in all sites, and thus data are not available for
certain periods in some sites.
Statistical methods
Each individual contributed exposure time during their
residence episodes in the DSS, which is from entry into
the DSS until exit due to migration, death, or censoring
at the time of the latest survey (or refusal to continue,
where relevant). Returning migrants, individuals who re-
entered the study following out-migration, contributed
person years only from the time they were resident in the
study site (i.e. between first entry and first exit and
between each subsequent entry and exit, as applicable).
To calculate mortality attributable to HIV, age-specific
mortality rates for HIV-negative people were applied to
the HIV-positive person years to calculate the number
of deaths expected in the HIV-positive group, had that
group experienced the mortality rates of the HIV-
negative individuals. The number of excess deaths were
classified as HIV attributable, and they were summarized
over the time periods and over sex and age groups.
The age and sex composition of the populations
differed between sites and over the ART phases. Mortal-
ity rates were standardized to allow comparison between
sites and across ART phases. The standard population
was the total number of person years contributed from all
sites in all ART phases.
A series of exponential regression models were fitted,
stratified by 5-year age group, to compare the mortality
rate among PLWH to that among HIV-negative indivi-
duals. The baseline group for comparison was HIV-
negative individuals in the later period when ART was
widely available. Mortality amongst HIV-negative indivi-
duals in the two earlier phases, and mortality among
PLWH in each ART phase, were compared by fitting an
interaction term in the model between HIV status and
ART phase. Sex and study site were included in the model
as fixed effects, and the standard errors were adjusted for
clustering by study site. By analyzing the data in this way,
the additional mortality due to HIV can be captured,
since HIV-negative individuals experienced a baseline
level of mortality. Data from Karonga were not included
Table 2. Classiﬁcation of deaths and exposure time by HIV
status
HIV-negative
HIV-
positive HIV status unknown
Between successive
negative tests
Following
any
positive
test
Never tested
Up to X years following
a negative
test with no other
subsequent test
Not yet tested (i.e. Before
first test,
whether or not that first
test was positive or
negative)
In a seroconversion
interval less
than X years duration
(negative
test followed by
positive test)
More than X years
following the last negative
test
X was based on observed incidence rates in the sites, and the
values used were 2 years in uMkhanyakude, 3 years in Rakai, and
5 years elsewhere.
HIV-attributable mortality by availability of ART
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ART phase. Those with unknown HIV status were in-
cluded in this model to account for differences over time
in the ascertainment of HIV status. These differences are
most apparent in the two sites with the most recent intro-
duction of HIV testing (Karonga and uMkhanyakude).
Results
The five study sites provided data on 244,769 adults aged
15 and older, who contributed a total of 1,149,484 person
years. This analysis is concerned with the mortality of the
127,585 adults age 15 years and above who have known
HIV status and who contributed 487,242 person years.
Table 3 shows for each site the number of subjects, person
years, the mortality rate, and the period prevalence of
HIV. The period prevalence of HIV was stable in Kisesa
and Rakai, showed a moderate increase in Masaka, and
showed a steep increase in uMkhanyakude. The propor-
tion of all deaths that were in known HIV positive
individuals declined over the three periods in all four sites
where this comparison was possible. All-cause mortality
ranged from 7 to 19 deaths per 1,000 person years.
The standardized mortality rates given in Table 4 show
the mortality rates for HIV-negative individuals and
PLWH and the excess mortality rate among PLWH, by
site, ART phase, and sex. These rates are standardized to
adjust for differences in the age composition between
sites and over ART phases. In all groups, the excess
mortality rate among PLWH was almost as high as the
total mortality rate for PLWH and much higher than the
mortality rate among HIV-negative individuals. The HIV-
positive mortality rate varied considerably between the
sites, and the excess mortality rate reflected that. With the
exception of men in Rakai, declines are apparent in both
the HIV positive overall and excess mortality, comparing
post-ARTrollout with the time before ARTwas available.
Before the advent of ART, the excess mortality rate
among PLWH was higher for men than for women. For
men and women, excess mortality was highest in Masaka
and lowest in Rakai. When ART became available, the
mortality rates fell; the extent of the decrease varied
between the site and across the sites by age group. Figure 1
shows the excess mortality rates by age, sex, and ART
phase for Kisesa, Masaka, Rakai, and uMkhanyakude.
Excess mortality rates for Karonga can only be estimated
for the post-ART phase and hence are not shown in
Fig. 1. In general, the most pronounced falls were in the
older age groups, whereas among 1519-year-old men in
Table 3. Number of subjects and person years contributed to the analysis, mortality rate and period prevalence of HIVamongst
persons with known HIV status, and the proportion of all deaths that were of individuals known to be HIV positive
ART phase
Number of
subjects Person years Deaths Mortality rate
Period
prevalence
HIV-positive
deaths (% of total)
Karonga
05 years before ART * * * * * *
ART introduction * * * * * *
ART available 18,159 46,134 316 6.8 7.4 25.9
Kisesa
05 years before ART 13,153 34,491 412 11.9 5.2 31.8
ART introduction 12,014 27,234 317 11.6 5.0 25.6
ART available 11,303 21,639 185 8.5 5.6 25.4
Masaka
05 years before ART 10,873 31,336 500 16.0 5.6 42.8
ART introduction 8,275 7,268 107 14.7 5.8 34.6
ART available 12,610 39,867 436 10.9 6.6 25.9
Rakai
05 years before ART 22,845 66,327 616 9.3 12.8 79.7
ART introduction 20,814 31,426 243 7.7 12.7 77.8
ART available 28,289 72,732 588 8.1 12.6 67.0
uMkhanyakude
05 years before ART 12,470 10,177 177 17.4 20.6 82.5
ART introduction 18,458 25,625 405 15.8 22.3 75.8
ART available 29,346 72,987 1,349 18.5 27.1 55.6
All sites pooled
05 years before ART 59,341 142,330 1,705 12.0 9.9 57.6
ART introduction 59,561 91,553 1,072 11.7 12.5 57.3
ART available 99,707 253,359 2,874 11.3 14.3 48.2
*Estimate not available.
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women in Rakai, excess mortality rates increased slightly.
The impact of ART availability is shown in Fig. 2 and
Table 5, which contain results from an age-stratified
exponential regression model comparing the mortality of
PLWH and HIV-negative individuals.
Figure 2 shows that the mortality of HIV-negative
individuals changed little between the three ART periods;
the only significant difference was that the mortality of
1519 year olds was slightly higher in the earliest period
(pre-ART). Within each age group, the mortality of
PLWH remained much higher than that of HIV-negative
people, even following the introduction of ART. Among
3034 year olds, the risk of mortality for a PLWH before
the introduction of ART was 30 times higher (95% CI:
1851) than that of an HIV-negative person. Following
the introduction of ART, the relative mortality hazard
had more than halved, but it remained 13 times higher
(95% CI: 1116) than that of HIV-negative individuals. In
the introductory phase of ART, the mortality reduction
was greatest at younger ages (those younger than 35, the
peak group for mortality). After ART was fully estab-
lished, mortality risk declined in older age groups, which
meant that the excess mortality risk among PLWH was
more uniformly distributed across the age range, with a
hazard ratio (HR) of 12 (95% CI: 916) in 1519 year
olds, 13 (95% CI: 1116) in 3034 year olds, and 5 (95%
CI: 46) among 5054 year olds.
Differences are apparent between the study sites at
different ages, reflecting the age-specific incidence pat-
tern. Masaka, Rakai, and uMkhanyakude’s mortality
was higher than Kisesa’s between the ages of 20 and 44.
Mortality in uMkhanyakude remained higher than that
of the other sites in the older age groups as well. There
were also differences between the sexes at different ages:
women’s mortality hazard was higher than men’s in the
20- to 24-year-old age group; and, from the age of 30, the
direction of this association reversed and men’s mortality
risk was higher than women’s such that by their late 40s,
women’s risk of dying was 60% that of men.
The changes between the ART phases are evident with
respect to a fixed comparison group. The models do not
show whether, between the ART phases, the mortality
changes among the PLWH are likely to be true. Separate
analysis, not shown, comparing the mortality changes
between the phases among PLWH using stratified
exponential regression confirms that the changes ob-
served are highly unlikely to be due to chance. There was
a significant difference between the mortality hazards for
each ART phase. For PLWH in their 20s and older, the
Table 4. Age-standardized mortality rates (per 1,000 person years) by site, sex, HIV status, and ART phase: rates for HIV-
negative people and PLWH, the excess mortality rate among PLWH (rate difference), and the standardized mortality ratio
(SMR)
Men Women
Site and ART phase
HIV-negative
mortality rate
HIV-positive
mortality rate Attributable SMR
HIV-negative
mortality rate
HIV-positive
mortality rate Attributable SMR
Karonga
05 years before ART    
ART introduction    
ART available 2.5 24.4 22.0 10 1.7 15.0 13.7 8.8
Kisesa
05 years before ART 3.6 55.2 51.6 15.3 4.2 52.4 48.7 12.5
ART introduction 5.2 47.1 42.2 9.1 3.2 39.8 36.9 12.4
ART available 3.2 33.8 30.8 10.6 1.8 19.6 18.3 10.9
Masaka
05 years before ART 3.9 88.0 84.8 22.6 3.2 91.5 88.3 28.6
ART introduction 2.8 77.4 75.4 27.6 3.5 60.5 58.0 17.3
ART available 3.8 43.6 39.9 11.5 2.3 30.3 28.3 13.2
Rakai
05 years before ART 2.3 42.5 40.6 17.7 1.7 45.7 43.9 25.8
ART introduction 2.2 31.1 28.9 13.1 1.0 32.8 31.8 31.8
ART available 3.2 49.4 46.2 14.4 2.5 28.3 25.8 10.3
uMkhanyakude
05 years before ART 7.6 63.4 56.2 8.3 1.8 56.7 54.9 31.5
ART introduction 8.3 47.4 39.5 5.7 2.1 38.3 36.1 18.2
ART available 5.7 43.2 37.5 7.6 1.6 22.6 21.1 14.1
HIV-attributable mortality by availability of ART
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post-ART phase. No difference in mortality was apparent
for teenagers living with HIV.
Discussion
Assessment of the mortality attributable to HIV re-
quires information on HIV serostatus and cause of death.
In countries where there is no adequate system of vital
registration, DSSs provide important estimates of levels
and trends in mortality. The members of the ALPHA
network, whose data are used here, combine the informa-
tion from demographic surveillance with information on
HIV serostatus from serological surveillance.
From these five sites, we have HIV status data on a
large proportion of five distinct populations covering
areas of very different HIV prevalence. These data can be
used to look at trends in HIV-positive mortality rates and
the excess mortality in PLWH. Excess mortality rates are
obtained from the difference between the mortality rate
of the PLWH and the mortality rate of the HIV-negative
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Fig. 1. Estimated excess mortality rate among PLWH by age, sex, and ART phase.
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Citation: Glob Health Action 2014, 7: 22789 - http://dx.doi.org/10.3402/gha.v7.22789Table 5. Hazard ratios and 95% conﬁdence intervals from an age-stratiﬁed exponential model comparing the mortality of PLWH and HIV-negative individuals by ART phase
ART phase and
HIV status 1519 2024 2529 3034 3539 4044 4549 5054
Pre-ART HIV  1.53
(1.142.05)
0.75
(0.441.25)
0.83
(0.691.00)
1.31
(0.483.54)
1
(0.571.74)
1.2
(0.512.82)
1.4
(0.702.84)
0.94
(0.541.62)
Pre-ART HIV 8.29
(6.2111.0)
17.38
(13.6622.1)
22.96
(18.3228.7)
30.3
(18.1750.5)
18.27
(10.0433.2)
19.2
(15.9623.1)
17.83
(11.8726.7)
11.49
(5.7323.0)
Pre-ART HIV? 2.07
(1.552.76)
4.22
(2.856.25)
7.11
(4.6310.9)
9.45
(6.5113.7)
5.85
(4.377.83)
4.97
(3.806.50)
3.66
(3.094.33)
1.9
(1.742.07)
ART intro HIV  0.97
(0.591.59)
1.39
(0.782.46)
1.3
(0.802.10)
1.26
(0.453.52)
1.18
(0.334.22)
1
(0.571.74)
1.18
(0.831.67)
1.17
(0.721.92)
ART intro HIV 3.76
(1.797.90)
12.22
(9.2716.1)
12.57
(9.3116.9)
17.38
(12.2224.7)
17.76
(15.8119.9)
15.1
(14.4915.7)
11.33
(8.7614.6)
9.45
(5.2017.1)
ART intro HIV? 2.01
(1.692.38)
3.11
(1.626.00)
6.56
(4.459.67)
8.79
(4.9215.6)
4.72
(3.157.10)
4.19
(2.826.23)
2.75
(2.043.70)
2.18
(1.772.67)
Post-ART HIV  11111111
Post-ART HIV 11.85
(8.8115.9)
8.7
(7.0210.7)
11.33
(7.9516.1)
13.09
(10.9915.5)
9.4
(7.8911.2)
8.35
(5.3313.0)
6.84
(5.149.11)
5
(4.235.91)
Post-ART HIV? 2.26
(1.343.79)
3.72
(2.276.08)
6.34
(3.4811.5)
7.93
(5.3311.8)
5.03
(4.136.13)
4.07
(2.586.42)
2.87
(2.133.87)
2.07
(1.333.23)
Sex
M e n 11111111
Women 1.02
(0.931.11)
1.32
(1.121.56)
1.06
(0.981.16)
0.9
(0.761.06)
0.75
(0.491.15)
0.59
(0.440.79)
0.57
(0.450.72)
0.53
(0.420.68)
Study site
Kisesa 1 1 1 1 1 1 1 1
Masaka 0.98
(0.881.09)
1.92
(1.662.21)
1.91
(1.752.10)
2.07
(1.852.30)
1.56
(1.421.71)
1.19
(1.061.34)
1.29
(1.181.40)
0.94
(0.920.96)
Rakai 0.94
(0.881.01)
1.35
(1.261.44)
1.74
(1.611.88)
1.87
(1.742.00)
1.62
(1.521.73)
1.12
(1.031.23)
0.99
(0.911.07)
1.18
(1.101.26)
uMkhanyakude 0.88
(0.790.99)
1.5
(1.391.62)
1.97
(1.842.11)
2.36
(2.102.64)
1.79
(1.542.08)
1.64
(1.401.92)
1.76
(1.561.99)
1.66
(1.471.87)
These results are from the same model as the estimates presented in Fig. 2.
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)individuals. In all sites, at least 90% of the deaths among
PLWH were attributable to HIV: they were in excess of
the deaths that would be expected given background
mortality rates among the HIV-negative population.
In the Karonga district of Malawi, the fraction of
mortality in the population attributable to HIV has
decreased since the advent of ART (25). In this analysis,
Karonga is the site with the lowest overall and excess
mortality among PLWH.
The reasons for this excess are unknown. If HIV in-
fection remains undiagnosed, the individual cannot access
treatment and lower their risk of dying. Suboptimal
treatment and associated care may not be enough to
prevent death. Late presentation may make it unlikely
that treatment will succeed. Data on individual experi-
ence of HIV diagnosis, treatment, and care will help to
explain why mortality remains high. These data are diffi-
cult to collect from the general population and insuffi-
cient data were available at the point of writing, but
future analyses are planned.
Two large international trials showed that among
PLWH who achieve adequate viral suppression and
CD4
 T-cell counts of at least 500 cells/ml, the mortality
rate is the same as that experienced by the general
population (26). A European study reached a similar
conclusion, finding in a clinical cohort that the standar-
dized mortality ratio (SMR) was 4.2, but in the subset of
individuals with a CD4 count higher than 500/mm
3, the
SMR was 1.5 (27). The International Epidemiologic
Databases to Evaluate AIDS (IeDEA) consortium car-
ried out an analysis of PLWH receiving ART in Co ˆte
d’Ivoire, Malawi, South Africa, and Zimbabwe; they
found that, among people who started ART with a CD4
count over 200 and at World Health Organization
(WHO) clinical stage I or II, the mortality rate was
very similar to that of the general population (28).
However, the same study estimated an overall HIV-
attributable mortality rate of 69.5 per 1,000 person-years
among the entire group receiving treatment and an SMR
of 18.7. These estimates are higher than those reported in
this article, and one reason could be that the follow-up
ended in 2007 when ART programmes were still quite
new. Analysis of data from 13 clinical cohort studies with
follow-up between 1996 and 2006 found a crude death
rate of 12.1 per 1,000 person years among PLWH
receiving ART (29). Another analysis of nine cohorts
found crude mortality rates among PLWH on ART that
ranged from 2.9 to 22.9 per 1,000 person years, with a
pooled crude rate of 9.5 per 1,000 (30).
However, the people identified as living with HIV in
the ALPHA studies are from population-based cohorts,
which include those who are on ART, those who have not
yet started ART, and those who are undiagnosed. Unlike
the clinical cohort studies, participants in the observa-
tional ALPHA cohorts may remain undiagnosed or
untreated at an advanced stage of infection, even once
ART is available. This might explain the higher mortality
rate among PLWH in the ALPHA sites compared to the
rates estimated from studies in Europe and North
America. The HIV-positive mortality rates from some
of the ALPHA sites lie within the range from the clinical
cohorts, even though ART coverage does not reach 100%
in any site. This may be because the ALPHA sites
regularly test all individuals who participate in the
studies, and many of those subsequently identified as
living with HIV will be at the early stages of HIV
infection and initially experience little excess mortality.
Individuals like this are likely to be underrepresented
in a clinical cohort. This may also explain why the
ALPHA estimates are lower than those from the IeDEA
study (28).
A strength of these results is that the estimation of
background mortality is directly measured  available
from the same population and at the same time  whereas
most previous studies have relied on national estimates.
The validity of these findings depends on the assumption
that the ascertainment of HIV status is essentially
complete, with the HIV status and stage of infection
among those who have not been tested assumed to be the
same as among those whose status is known. If this is not
the case, then the true difference in mortality between
PLWH and HIV-negative individuals may be different
from that estimated. The proportion of individuals (aged
15) in the DSS for whom HIV status had never been
measured, by the end of the last phase of follow-up,
ranged from 16% in Masaka (the longest running study)
to 60% in uMkhanyakude (the site with the shortest
history of HIV testing).
In this article, we have not used data on cause of death
to distinguish AIDS mortality from other causes of death
among PLWH, which is another way of estimating
mortality attributable to HIV. Population-based cause-
of-death information is not routinely available in these
countries. A variable proportion of recorded deaths in
ALPHA sites have had a verbal autopsy (VA) done. VA
data can be used to assign a probable cause of death for
people dying outside hospital settings either by physician
review or through the use of software. We have not used
VA data in this article because the differences in VA
coverage between the sites, and over time, are sufficient to
undermine our ability to make comparisons between sites
and over time.
VA data have been used to show that HIV-associated
deaths are a major contributor to adult mortality in
different sub-Saharan African populations (25, 31). VA
data have also been used to show the share of AIDS
deaths in the population as a whole, which depends on
the prevalence of HIV in the population as well as the
background mortality in HIV-negative individuals.
Emma Slaymaker et al.
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cause-specific mortality estimates by modeling data from
a variety of sources. They estimated that the proportion
of all deaths attributable to HIV/AIDS was highest in
South Africa (41.1%) and lower in Malawi (23.6%),
Tanzania (21.2%), and Uganda (17.2%). In each of these
countries, they estimated that HIV/AIDS is the leading
cause of disease burden (32). When ART was available in
the Malawi and Tanzanian sites, and one of the Ugandan
sites, we estimate that 25% of deaths occurred in people
known to be living with HIV. In the other Ugandan site,
Rakai, the estimate was much higher (67%). Historically,
HIV incidence and prevalence have been higher in Rakai
than Masaka. Since 2005, ARTand circumcision services
have been available in Rakai, and HIV incidence has
fallen. Mortality in Rakai among PLWH and HIV-
negative people has been lower than in Masaka, and
this difference was especially pronounced before ART
was available. This may have been due to research
activities in Rakai which included active follow-up for
participants who tested HIV-positive, a system of com-
munity counselors, mobile clinics which provided sexually
transmitted infection treatment and referrals to the static
clinics, and nevirapine for pregnant and breastfeeding
women with HIV. These activities may have lowered
mortality among known PLWH prior to ART treatment
being widely available.
Mortality declines have been seen following the intro-
duction of ART. Once treatment programmes were widely
available, PLWH mortality fell to about half of the level
it was before the introduction of ART. However, PLWH
retain a high level of excess mortality with almost 10
deaths to every 1 that would be expected.
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